1519PD PHASE II STUDY OF AMRUBICIN IN PATIENTS WITH REFRACTORY OR RESISTANT RELAPSED SMALL-CELL LUNG CANCER: JAPAN CLINICAL ONCOLOGY GROUP STUDY (JCOG0901)

that ORR = <10%, 95% CI, 22.9% to 44.2%), with two complete responses and 25 partial responses according to independent assessments.Median PFS and OS were 3.5 months (95% CI, 3.0 to 4.3 months) and 8.9 months (95% CI, 7.6 to 11.3 months), respectively. The most common grade 3 and 4 adverse events were neutropenia (93.9%), leukopenia (85.4%), anemia (25.6%) and thrombocytopenia (20.7%). Twenty-two patients (26.8%) experienced febrile neutropenia. No treatment-related death was observed. Conclusions: Amrubicin demonstrated the favorable tumor response and survival with acceptable toxicity. Single-agent amrubicin could be considered as a standard regimen in the treatment of refractory or resistant relapsed SCLC. Disclosure: All authors have declared no conflicts of interest.